Sanofi is buying Vicebio, a biotech, that is developing vaccines for two viruses using the molecular clamp technology ...

The acquisition, which will give Sanofi a combination vaccine for respiratory syncytial virus and human metapneumovirus, ...

The deal complements an existing partnership with Novavax that encompasses R&D of combination vaccines for Covid-19 and flu.

PARIS] Sanofi agreed to buy UK biotech Vicebio for as much as US$1.6 billion, gaining experimental vaccines and a technology ...

Sanofi said May 17 it will soon launch a late-stage trial for the COVID-19 vaccine it is developing with GlaxoSmithKline after the vaccine produced a strong immune response in phase 2 trial ...

Earlier this summer the FDA asked Moderna for more efficacy data on its flu vaccine before it could review an mRNA-based ...

Sanofi Deal Breathes New Life Into NVAX Stock Beginning next year, Sanofi will gain rights to co-market Novavax’s COVID-19 vaccine globally, except in certain countries where the company has ...

Sanofi and GlaxoSmithKline said Oct. 28 that they will provide 200 million doses of their COVID-19 vaccine to the World Health Organization's Covax initiative if the vaccine receives regulatory ...

Novavax reports strong immune responses from H5N1 avian flu vaccine candidate, showing promise in single and two-dose ...

Drugmakers are racing to develop what would be a lucrative prize, but have sought financial support to mitigate the risks. Sanofi is working on two vaccine projects against COVID-19.